Advanced search
Publication Cover
Molecular and Cellular Biology Volume 21, 2001 - Issue 3
Submit an article Journal homepage
19
Views
97
CrossRef citations to date
0
Altmetric
Cell Growth and Development

The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl

Xiaowu Zhang1 Rosenstiel Basic Medical Sciences Research Center;2 Department of Biochemistry
,
Ramesh Subrahmanyam1 Rosenstiel Basic Medical Sciences Research Center;3 Department of Biology, Brandeis University, Waltham, Massachusetts02454-9110
,
Ray Wong1 Rosenstiel Basic Medical Sciences Research Center;3 Department of Biology, Brandeis University, Waltham, Massachusetts02454-9110
,
Alec W. Gross1 Rosenstiel Basic Medical Sciences Research Center;3 Department of Biology, Brandeis University, Waltham, Massachusetts02454-9110
&
Ruibao Ren1 Rosenstiel Basic Medical Sciences Research Center;3 Department of Biology, Brandeis University, Waltham, Massachusetts02454-9110Correspondence[email protected]
Pages 840-853 | Received 17 Jul 2000, Accepted 13 Nov 2000, Published online: 27 Mar 2023

Citations (97)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Theodora S Ross & Victoria E Mgbemena. (2014) Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia. Molecular & Cellular Oncology 1:3.
Read now
Da-Qiang Li, Sujit S. Nair & Rakesh Kumar. (2013) The MORC family. Epigenetics 8:7, pages 685-693.
Read now
Andrew S. Dixon & Carol S. Lim. (2010) The Nuclear Translocation Assay for Intracellular Protein-Protein Interactions and its Application to the Bcr Coiled-Coil Domain. BioTechniques 49:1, pages 519-524.
Read now
Alfonso Quintás-Cardama, Hagop Kantarjian & Jorge Cortes. (2006) Targeting Abl and Src Kinases In Chronic Myeloid Leukemia: Experience With Dasatinib. Future Oncology 2:6, pages 655-665.
Read now
Lolita Banerji & Martin Sattler. (2004) Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias. Expert Opinion on Therapeutic Targets 8:3, pages 221-239.
Read now
Ryan P. Million, Nari Harakawa, Sergei Roumiantsev, Lyuba Varticovski & Richard A. Van Etten. (2004) A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Molecular and Cellular Biology 24:11, pages 4685-4695.
Read now
Stephan M. Feller, Gabriele Tuchscherer & Jan Voss. (2003) High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia. Leukemia & Lymphoma 44:3, pages 411-427.
Read now
Ruibao Ren. (2002) Dissecting the Molecular Mechanism of Chronic Myelogenous Leukemia Using Murine Models. Leukemia & Lymphoma 43:8, pages 1549-1561.
Read now

Articles from other publishers (89)

Omar S. El-Masry. (2023) Gene expression profile and presentation of novel gene variants of <i>COX7B</i> and <i>COX7C</i> in a cohort of patients with chronic myeloid leukemia. Electronic Journal of General Medicine 20:3, pages em468.
Crossref
Yonglan Liu, Mingzhen Zhang, Hyunbum Jang & Ruth Nussinov. (2022) Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire . Protein Science 32:1.
Crossref
Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney & Ruth Nussinov. (2022) The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia. Biophysical Journal 121:12, pages 2251-2265.
Crossref
Hui Mu, Xiaojian Zhu, Hui Jia, Lu Zhou & Hong Liu. (2021) Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. Frontiers in Oncology 11.
Crossref
Mohammad Al Hamad. (2022) Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Research 10, pages 1288.
Crossref
Mohammad Al Hamad. (2021) Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Research 10, pages 1288.
Crossref
Jevon A. Cutler, Savita Udainiya, Anil K. Madugundu, Santosh Renuse, Yaoyu Xu, Jaehun Jung, Kwang Pyo Kim, Xinyan Wu & Akhilesh Pandey. (2019) Integrative phosphoproteome and interactome analysis of the role of Ubash3b in BCR-ABL signaling. Leukemia 34:1, pages 301-305.
Crossref
Marc G. Berger & Céline Bourgne. 2019. Stem Cells Heterogeneity in Cancer. Stem Cells Heterogeneity in Cancer 171 185 .
Qian Zhang, Yao Li, Rongrong Zhao, Xinyi Wang, Chuling Fan, Youzhi Xu, Yakun Liu, Jiabin Li & Siying Wang. (2018) The gain‐of‐function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β‐catenin signaling pathway. Molecular Carcinogenesis 57:5, pages 619-628.
Crossref
S Gu, A Sayad, G Chan, W Yang, Z Lu, C Virtanen, R A Van Etten & B G Neel. (2017) SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia 32:1, pages 203-213.
Crossref
Marina Konopleva, Alfonso Quintás Cardama, Hagop Kantarjian & Jorge Cortes. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 29 47 .
Lingdi Ma, Zhenyu Xu, Jian Wang, Zhichao Zhu, Guibin Lin, Lijia Jiang, Xuzhang Lu & Chang Zou. (2017) Matrine inhibits BCR/ABL mediated ERK/MAPK pathway in human leukemia cells. Oncotarget 8:65, pages 108880-108889.
Crossref
Atul Kumar, Jina Bhattacharyya & Bithiah Grace Jaganathan. (2017) Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways. Scientific Reports 7:1.
Crossref
Zhi-Jie Kang, Yu-Fei Liu, Ling-Zhi Xu, Zi-Jie Long, Dan Huang, Ya Yang, Bing Liu, Jiu-Xing Feng, Yu-Jia Pan, Jin-Song Yan & Quentin Liu. (2016) The Philadelphia chromosome in leukemogenesis. Chinese Journal of Cancer 35:1.
Crossref
Gerald Webersinke. (2016) Molecular pathogenesis of chronic myeloid leukemia. memo - Magazine of European Medical Oncology 9:4, pages 163-167.
Crossref
Elizabeth Sloan, Anne Orr & Roger D. Everett. (2016) MORC3, a Component of PML Nuclear Bodies, Has a Role in Restricting Herpes Simplex Virus 1 and Human Cytomegalovirus. Journal of Virology 90:19, pages 8621-8633.
Crossref
Shengqing GuWayne W. ChanGolam Mohi, Joel RosenbaumAzin SayadZhibin LuCarl VirtanenShaoguang Li, Benjamin G. NeelRichard A. Van Etten. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127:14, pages 1803-1813.
Crossref
Philippa C. May, Jamshid S. Khorashad, Mary Alikian, Danilo Perrotti & Alistair G. Reid. 2016. The Genetic Basis of Haematological Cancers. The Genetic Basis of Haematological Cancers 312 358 .
Isabella Haberbosch, Anahita Rafiei, Claudia Oancea, Oliver Gerhart Ottmann, Martin Ruthardt & Afsar Ali Mian. (2016) BCR: a new target in resistance mediated by BCR/ABL-315I?. Genes & Cancer 7:1-2, pages 36-46.
Crossref
Bradley Chereda & Junia V. Melo. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia 17 39 .
WeiXu Ma, Ning Ma, XiaoHui Chen, YiYue Zhang & WenQing Zhang. (2015) An overview of chronic myeloid leukemia and its animal models. Science China Life Sciences 58:12, pages 1202-1208.
Crossref
Bradley Chereda & Junia V. Melo. (2015) Natural course and biology of CML. Annals of Hematology 94:S2, pages 107-121.
Crossref
Paolo GallipoliAmy Cook, Susan RhodesLisa HopcroftHelen WheadonAnthony D. Whetton, Heather G. JørgensenRavi Bhatia & Tessa L. Holyoake. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 124:9, pages 1492-1501.
Crossref
Julieta Politi & Neil P. Shah. (2014) What Does a Deep Molecular Response Signify?. Journal of Clinical Oncology 32:5, pages 471-474.
Crossref
Jessica Fredericks & Ruibao Ren. (2013) The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia. Frontiers of Medicine 7:4, pages 452-461.
Crossref
Wolfgang Warsch, Christoph Walz & Veronika Sexl. (2013) JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 122:13, pages 2167-2175.
Crossref
L C Gillis, D M Berry, M D Minden, C J McGlade & D L Barber. (2013) Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia. Leukemia 27:8, pages 1666-1676.
Crossref
K M Badger-Brown, L C Gillis, M L Bailey, J M Penninger & D L Barber. (2012) CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing. Leukemia 27:5, pages 1146-1154.
Crossref
Zheng-Lan Huang, Miao Gao, Mao-Sheng Ji, Kun Tao, Qing Xiao, Liang Zhong, Jian-Ming Zeng & Wen-Li Feng. (2012) TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization. Amino Acids 44:2, pages 461-472.
Crossref
David W. Woessner & Carol S. Lim. (2012) Disrupting BCR-ABL in Combination with Secondary Leukemia-Specific Pathways in CML Cells Leads to Enhanced Apoptosis and Decreased Proliferation. Molecular Pharmaceutics 10:1, pages 270-277.
Crossref
Alfonso Quintás Cardama, Hagop Kantarjian & Jorge Cortes. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 29 44 .
Daniela Cilloni & Giuseppe Saglio. (2012) Molecular Pathways: BCR-ABL. Clinical Cancer Research 18:4, pages 930-937.
Crossref
A-Reum Park, Daeyoung Oh, So-Hee Lim, Jeonghoon Choi, Jeonghee Moon, Dae-Yeol Yu, Sung Goo Park, Nora Heisterkamp, Eunjoon Kim, Pyung-Keun Myung & Jae-Ran Lee. (2012) Regulation of dendritic arborization by BCR Rac1 GTPase-activating protein, a new substrate of protein tyrosine phosphatase receptor T. Journal of Cell Science.
Crossref
Andrew S. Dixon, Scott S. Pendley, Benjamin J. Bruno, David W. Woessner, Adrian A. Shimpi, Thomas E. CheathamIIIIII & Carol S. Lim. (2011) Disruption of Bcr-Abl Coiled Coil Oligomerization by Design. Journal of Biological Chemistry 286:31, pages 27751-27760.
Crossref
Zhenglan Huang, Maosheng Ji, Zhi Peng, Shifeng Huang, Qing Xiao, Chunli Li, Jianming Zeng, Miao Gao & Wenli Feng. (2011) Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells. Biomedicine & Pharmacotherapy 65:3, pages 183-192.
Crossref
Eric Padron, Lori A. Hazlehurst & Javier Pinilla‐Ibarz. 2011. Advances in Malignant Hematology. Advances in Malignant Hematology 62 70 .
A Samanta, B Perazzona, S Chakraborty, X Sun, H Modi, R Bhatia, W Priebe & R Arlinghaus. (2010) Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia. Leukemia 25:3, pages 463-472.
Crossref
Martin Preyer, Paolo Vigneri & Jean Y. J. Wang. (2011) Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL. PLoS ONE 6:2, pages e17020.
Crossref
H Modi, L Li, S Chu, J Rossi, J-K Yee & R Bhatia. (2010) Inhibition of Grb2 expression demonstrates an important role in BCR–ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia 25:2, pages 305-312.
Crossref
S Chu, T McDonald & R Bhatia. (2010) Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors. Leukemia 24:4, pages 779-787.
Crossref
Yaoyu Chen, Cong Peng, Dongguang Li & Shaoguang Li. (2010) Molecular and cellular bases of chronic myeloid leukemia. Protein & Cell 1:2, pages 124-132.
Crossref
Alfonso Quintás-Cardama & Jorge Cortes. (2009) Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood 113:8, pages 1619-1630.
Crossref
Karina J Baum & Ruibao Ren. (2008) Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis. Journal of Hematology & Oncology 1:1.
Crossref
T Pene-Dumitrescu, L F Peterson, N J Donato & T E Smithgall. (2008) An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 27:56, pages 7055-7069.
Crossref
Margret S. RodriguesMamatha M. ReddyMartin Sattler. (2008) Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications. Antioxidants & Redox Signaling 10:10, pages 1813-1848.
Crossref
Kim De Keersmaecker, Jennifer L. Rocnik, Rafael Bernad, Benjamin H. Lee, Dena Leeman, Olga Gielen, Hanne Verachtert, Cedric Folens, Sebastian Munck, Peter Marynen, Maarten Fornerod, D. Gary Gilliland & Jan Cools. (2008) Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore. Molecular Cell 31:1, pages 134-142.
Crossref
Tim Beissert, Alena Hundertmark, Velina Kaburova, Lorena Travaglini, Afsar A. Mian, Clara Nervi & Martin Ruthardt. (2008) Targeting of the N‐terminal coiled coil oligomerization interface by a helix‐2 peptide inhibits unmutated and imatinib‐resistant BCR/ABL. International Journal of Cancer 122:12, pages 2744-2752.
Crossref
Gordon Chan, Demetrios Kalaitzidis & Benjamin G. Neel. (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer and Metastasis Reviews 27:2, pages 179-192.
Crossref
A Quintás-Cardama. (2008) Experimental non-ATP-competitive therapies for chronic myelogenous leukemia. Leukemia 22:5, pages 932-940.
Crossref
Ji WuFeng MengHenry Lu, Ling KongWilliam Bornmann, Zhenghong Peng, Moshe Talpaz & Nicholas J. Donato. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111:7, pages 3821-3829.
Crossref
R A Van Etten. (2007) Aberrant cytokine signaling in leukemia. Oncogene 26:47, pages 6738-6749.
Crossref
Su Chu, Liang Li, Harjeet Singh & Ravi Bhatia. (2007) BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia. Cancer Research 67:14, pages 7045-7053.
Crossref
Daniel J. DeAngelo. (2007) Role of Imatinib-Sensitive Tyrosine Kinases in the Pathogenesis of Chronic Myeloproliferative Disorders. Seminars in Hematology 44, pages S17-S30.
Crossref
Jing ChenWen-Mei YuHanako DainoHal E. BroxmeyerBrian J. Druker & Cheng-Kui Qu. (2006) SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109:2, pages 778-785.
Crossref
Junia V. Melo & John M. GoldmanDaniela Cilloni & Giuseppe Saglio. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders 15 35 .
Alfonso Quintás-Cardama & Jorge E. Cortes. (2006) Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings 81:7, pages 973-988.
Crossref
Dario Diviani, Laurent Baisamy & Aline Appert-Collin. (2006) AKAP-Lbc: A molecular scaffold for the integration of cyclic AMP and Rho transduction pathways. European Journal of Cell Biology 85:7, pages 603-610.
Crossref
Pamela H. Correll, Robert F. Paulson & Xin Wei. (2006) Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Gene 374, pages 26-38.
Crossref
Ruibao Ren. 2006. Abl Family Kinases in Development and Disease. Abl Family Kinases in Development and Disease 77 92 .
Oliver Hantschel & Giulio Superti-Furga. 2006. Abl Family Kinases in Development and Disease. Abl Family Kinases in Development and Disease 1 10 .
Oliver Hantschel, Silke Wiesner, Thomas Güttler, Cameron D. Mackereth, Lily L. Remsing Rix, Zsuzsanna Mikes, Jana Dehne, Dirk Görlich, Michael Sattler & Giulio Superti-Furga. (2005) Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl. Molecular Cell 19:4, pages 461-473.
Crossref
Laurent Baisamy, Nathalie Jurisch & Dario Diviani. (2005) Leucine Zipper-mediated Homo-oligomerization Regulates the Rho-GEF Activity of AKAP-Lbc. Journal of Biological Chemistry 280:15, pages 15405-15412.
Crossref
Michael G. Kharas & David A. Fruman. (2005) ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors . Cancer Research 65:6, pages 2047-2053.
Crossref
Ruibao Ren. (2005) Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer 5:3, pages 172-183.
Crossref
Scott C. Kogan. 2004. Mouse Models of Human Cancer. Mouse Models of Human Cancer.
Robert L IlariaJrJr. (2004) Animal models of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America 18:3, pages 525-543.
Crossref
Richard A Van Etten. (2004) Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leukemia Research 28, pages 21-28.
Crossref
Stephane WongOwen N. Witte. (2004) The BCR-ABL Story: Bench to Bedside and Back. Annual Review of Immunology 22:1, pages 247-306.
Crossref
Oliver Hantschel & Giulio Superti-Furga. (2004) Regulation of the c-Abl and Bcr–Abl tyrosine kinases. Nature Reviews Molecular Cell Biology 5:1, pages 33-44.
Crossref
Ralph Arlinghaus & Tong Sun. 2004. Molecular Targeting and Signal Transduction. Molecular Targeting and Signal Transduction 239 270 .
Tim BeissertElena PuccettiAndrea BianchiniSaskia GüllerSimone BoehrerDieter HoelzerOliver Gerhard OttmannClara NerviMartin Ruthardt. (2003) Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 102:8, pages 2985-2993.
Crossref
Jason A. WertheimSamanthi A. PereraDaniel A. HammerRuibao RenDavid BoettigerWarren S. Pear. (2003) Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood 102:6, pages 2220-2228.
Crossref
Thomas M. Eisenhaure, Sanjeev A. Francis, L.David Willison, Shaun R. Coughlin & Daniel J. Lerner. (2003) The Rho Guanine Nucleotide Exchange Factor Lsc Homo-oligomerizes and Is Negatively Regulated through Domains in Its Carboxyl Terminus That Are Absent in Novel Splenic Isoforms. Journal of Biological Chemistry 278:33, pages 30975-30984.
Crossref
Cornelius Miething, Rebekka Grundler, Falco Fend, Josef Hoepfl, Claudia Mugler, Christoph von Schilling, Stephan W Morris, Christian Peschel & Justus Duyster. (2003) The oncogenic fusion protein nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 22:30, pages 4642-4647.
Crossref
Kristen M. Smith, Rinat Yacobi & Richard A. Van Etten. (2003) Autoinhibition of Bcr-Abl through Its SH3 Domain. Molecular Cell 12:1, pages 27-37.
Crossref
Martin Sattlermc & James D. Griffin. (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Seminars in Hematology 40, pages 4-10.
Crossref
Martin Sattler, Blanca Scheijen, Ellen Weisberg & James D. Griffin. 2003. New Trends in Cancer for the 21stCentury. New Trends in Cancer for the 21stCentury 121 140 .
Ruibao Ren. (2002) The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21:56, pages 8629-8642.
Crossref
Jason A Wertheim, Juli P Miller, Lanwei Xu, Yiping He & Warren S Pear. (2002) The biology of chronic myelogenous leukemia:mouse models and cell adhesion. Oncogene 21:56, pages 8612-8628.
Crossref
Ralph B Arlinghaus. (2002) Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene 21:56, pages 8560-8567.
Crossref
Ryan P. MillionJon AsterD. Gary GillilandRichard A. Van Etten. (2002) The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 99:12, pages 4568-4577.
Crossref
Jason A. WertheimKevin ForsytheBrian J. DrukerDaniel HammerDavid BoettigerWarren S. Pear. (2002) BCR-ABL–induced adhesion defects are tyrosine kinase–independent. Blood 99:11, pages 4122-4130.
Crossref
Martin Sattler, M.Golam Mohi, Yuri B Pride, Laura R Quinnan, Nicole A Malouf, Klaus Podar, Franck Gesbert, Hiromi Iwasaki, Shaoguang Li, Richard A Van Etten, Haihua Gu, James D Griffin & Benjamin G Neel. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:5, pages 479-492.
Crossref
Blanca Scheijen & James D Griffin. (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21:21, pages 3314-3333.
Crossref
Yiping HeJason A. WertheimLanwei XuJuli P. MillerFredrick G. KarnellJohn K. ChoiRuibao RenWarren S. Pear. (2002) The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia–like disease by bcr/abl. Blood 99:8, pages 2957-2968.
Crossref
Nicholas C. WolffRobert L. IlariaJrJr. (2001) Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98:9, pages 2808-2816.
Crossref
Stephane Wong & Owen N Witte. (2001) Modeling Philadelphia chromosome positive leukemias. Oncogene 20:40, pages 5644-5659.
Crossref
Richard A. Van Etten. (2001) Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models. Current Opinion in Hematology 8:4, pages 224-230.
Crossref
Martin Sattler & James D. Griffin. (2001) Mechanisms of Transformation by the BCR/ABL Oncogene. International Journal of Hematology 73:3, pages 278-291.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.